AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 7 - (NewsRx.com & NewsRx.net) -- Autoantibodies to annexin XI-A and other autoantigens have potential as biomarker of breast cancer, researchers report.
F. Fernandez-Madrid, Wayne State University, and colleagues identified "autoantigens commonly recognized by sera from patients with breast cancer."
"We selected 10 sera from patients with invasive ductal carcinoma (IDC) of the breast with high titer immunoglobulin (Ig)G autoantibodies for biopanning of a T7 phage breast cancer cDNA display library," the researchers said.
They continued: "A high throughput method involved the assembly of 938 T7 phages encoding potential breast cancer autoantigens. Microarrays of positive phages were probed with sera from 90 patients with breast cancer [15 patients with ductal carcinoma in situ (DCIS) and 75 patients with IDC of the breast], with 51 non-cancer control sera and with sera from 21 patients with systemic autoimmune diseases."
The team also constructed "[a] 12-phage breast cancer predictor group ... with phage inserts recognized by sera from patients with breast cancer and not by non-cancer or autoimmune control sera (p
"Several autoantigens including annexin XI-A, the p80 subunit of the Ku antigen, ribosomal protein S6, and other unknown autoantigens could significantly discriminate between breast cancer and non-cancer control sera," reported Fernandez-Madrid and associates.
"Biopanning with three different sera led to the cloning of partial cDNA sequences identical to annexin XI-A. ...